New Preferred Characteristics for Monoclonal Antibodies in Malaria Prevention
Passive immunization through monoclonal antibodies (mAbs) could potentially provide immediate protection against malaria. To guide the development of urgently needed health products, WHO has published preferred product characteristics (PPCs) for mAbs in malaria prevention. These PPCs aim to reduce morbidity and mortality in infants and children due to Plasmodium falciparum, and highlight the preferred characteristics and clinical development considerations for mAbs in this area. This is an exciting development alongside the development of new malaria vaccines and chemoprevention drugs.
Recent Posts
Navigating Economic Resilience Through Life Sciences Investment
Navigating a Leaderless Global Economy Through Life Sciences Investment
In an era of deepening geopolitical fragmentation, often termed the G-Zero world, global governments are urged to prioritize bold life sci...
Driving Economic Transformation through Brain Health Investment in Africa
The Johannesburg Communiqué from the Africa Task Force on Brain Health declares that investing in brain health is crucial, as it supports Africa’s economic transformation and Agenda 2063 goals while covering dementia, mental health, brain trauma, and substance abuse. This investment aligns with N...
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity
Recent mRNA vaccine advancements are poised to transform global health by expanding beyond COVID-19 to tackle neglected infectious diseases and even therapeutic uses. Experts forecasting breakthroughs for 2026 highlight how these innovations use lipid nanoparticles to deliver RNA sequences encodi...